Fosamax and Osteonecrosis of the Jaw: Understanding Long-Term Prognosis

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specialized Risk Management

General health and science information has long served as a foundation for public understanding of medication safety and bone physiology. Within this broad domain, discussions of bisphosphonate therapies, such as Fosamax, have historically focused on their efficacy in managing osteoporosis and preventing fractures. The legacy context emphasizes the benefits of these treatments in maintaining skeletal integrity, with routine monitoring for common side effects like gastrointestinal discomfort. This established framework provides a baseline for evaluating therapeutic risk-benefit profiles in a general population. As clinical experience with bisphosphonates has accumulated, attention has shifted toward less common but more serious adverse outcomes. A notable pivot occurs when considering the specific exposure scenario of long-term Fosamax use and its association with osteonecrosis of the jaw (ONJ). This condition, characterized by exposed necrotic bone in the maxillofacial region, introduces a distinct occupational dimension. Dental professionals, oral surgeons, and healthcare workers involved in managing patients on bisphosphonate therapy face unique considerations regarding risk assessment, procedural planning, and patient counseling. The transition from general health information to this occupational exposure concern requires recognizing that the prognosis of ONJ—including healing potential, recurrence rates, and long-term functional outcomes—becomes a critical factor in clinical decision-making for practitioners who regularly encounter these cases. This shift reframes the discussion from population-level safety to specialized, practice-based risk management.

Mechanisms and Risk Factors for Fosamax-Associated ONJ

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use is associated with a rare but serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast-mediated bone resorption, which can suppress normal bone turnover and remodeling. This suppression is particularly impactful in the jawbone, which undergoes frequent remodeling due to dental procedures and masticatory forces. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The resulting imbalance between bone resorption and formation may impair the ability of the jawbone to heal after minor trauma, such as tooth extraction, leading to necrotic bone exposure. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Long-Term Prognosis and Outcomes After Fosamax Discontinuation

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, though a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Prognosis-related considerations for affected patients are critical. The long-term outcome of ONJ after Fosamax use depends on several factors, including the severity of the lesion, presence of infection, and the patient's overall health. Discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Most patients experience relief of symptoms after stopping the drug, but a subset may have persistent or recurrent symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ diminishes after discontinuation of antiresorptive therapy, as evidenced by the lower risk in past users compared to current users (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Clinical Management Guidance

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The warning advises discontinuation if severe symptoms develop and notes that most patients have relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide clinicians with guidance to mitigate risk, though the absolute risk remains low. In summary, ONJ is a rare but serious adverse effect of Fosamax, with risk increasing with duration of use. The prognosis is generally favorable after discontinuation, with most patients experiencing symptom relief. However, a subset may have persistent issues, and rechallenge with bisphosphonates can lead to recurrence. Adequate warnings are present in the prescribing information, emphasizing risk factors and management strategies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for osteonecrosis of the jaw after stopping Fosamax?

Most patients experience relief of symptoms after discontinuing Fosamax, but a subset may have persistent or recurrent symptoms. The risk of ONJ diminishes after discontinuation, as evidenced by lower risk in past users compared to current users (https://pubmed.ncbi.nlm.nih.gov/39400702/). Factors such as lesion severity, infection, and overall health influence outcomes.

How does the duration of Fosamax use affect the risk of developing ONJ?

The risk of ONJ increases with longer exposure to bisphosphonates. Among female osteoporosis patients, risk was threefold higher after 2-3 years and eightfold after 10 years compared with past use, though absolute risks remain low (approximately 0.05% after 5 years) (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the recommended management strategies for patients on Fosamax who require dental procedures?

Discontinuation of bisphosphonate treatment may reduce the risk of ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The prescribing information advises clinicians to weigh risks and benefits, and to consider drug discontinuation for 3-5 years in low-fracture-risk patients.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.